西酞普兰USP相关物质F

[ 分子式 ]:
C₂₃H₃₀N₂

[ 分子量 ]:
334.49800

[ 精确质量 ]:
334.24100

[ PSA ]:
6.48000

[ LogP ]:
4.25450

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301

[ 警示性声明 ]:
P301 + P310

[ 危害码 (欧洲) ]:
T

[ 风险声明 (欧洲) ]:
25

[ 安全声明 (欧洲) ]:
45

[ 危险品运输编码 ]:
UN 2811 6.1 / PGIII

Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.

Eur. J. Clin. Pharmacol. 19(3) , 217-23, (1981)

The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intrav...

The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene.

Pharmacol. Toxicol. 79(2) , 103-4, (1996)

Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.

Pharmacol. Toxicol. 82(3) , 157-60, (1998)

The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketob...

更多文献

公司名：上海化源世纪贸易有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：N,N,1-Trimethyl-3,3-diphenylallylamine Hydrochloride

---

查看所有供应商请点击：

西酞普兰USP相关物质F供应商